Amycretin: The Oral Weight Loss Pill That Could Replace Ozempic Injections in South Africa

If you are tired of weekly injections but want the weight loss power of Ozempic or Wegovy, Novo Nordisk may have the answer. Amycretin is a new oral weight loss pill -- a single tablet you swallow daily -- that activates both GLP-1 and amylin receptors at the same time. In early trials, it produced 13% body weight loss in just 12 weeks, a result that took injectable semaglutide considerably longer to match.

For South Africans who want the benefits of next-generation weight loss medication without needles, amycretin is arguably the most important drug in development right now. Here is everything we know about it.

What Is Amycretin and How Does It Work?

Amycretin is a unimolecular co-agonist -- a single peptide molecule engineered to activate two different receptor systems simultaneously:

• GLP-1 receptors -- the same target as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro). GLP-1 activation slows gastric emptying, reduces appetite through the hypothalamus, and improves insulin sensitivity.
• Amylin receptors -- located in the brainstem's area postrema. Amylin is a hormone co-secreted with insulin that promotes satiety through a different neural pathway than GLP-1. It tells your brain "you are full" via a completely separate signalling route.

This dual mechanism is the key differentiator. Where Ozempic works through one pathway (GLP-1 only) and CagriSema combines two separate injectable drugs to hit both pathways, amycretin achieves the same dual coverage in a single oral molecule. No injections. No mixing. One pill.

Amycretin Phase 1 Trial Results

Novo Nordisk presented Phase 1 data for amycretin showing rapid and significant weight loss in participants with overweight or obesity:

To put this in perspective: 13% weight loss in 12 weeks is exceptionally fast. Oral semaglutide (Rybelsus) typically produces around 6-8% weight loss over a much longer period. Injectable semaglutide 2.4mg (Wegovy) averages about 15% weight loss but requires 68 weeks to get there. Amycretin appears to achieve comparable results in a fraction of the time -- and without an injection.

Phase 1 trials are small and primarily designed to test safety and dosing, not efficacy. The weight loss figures are promising but need to be confirmed in larger Phase 2 and Phase 3 trials currently underway.

How Amycretin Compares to Existing Weight Loss Medications

The standout feature is the oral route. Every other high-performing weight loss drug in this table requires a weekly injection. Amycretin would be the first oral pill to deliver GLP-1-plus-amylin-level weight loss without a needle.

Why an Oral Pill Changes Everything

Needle avoidance is not a minor concern. Research consistently shows that a significant portion of patients prescribed injectable medications either delay starting, skip doses, or discontinue treatment due to injection anxiety. In South Africa specifically:

• Access: Injectable GLP-1 drugs require cold-chain storage and pharmacy dispensing. An oral tablet can be stored at room temperature and dispensed like any other pill.
• Cost potential: Oral formulations are generally cheaper to manufacture and distribute than prefilled injection pens. This could translate to lower ZAR pricing for South African patients.
• Adherence: A daily pill fits into existing routines more naturally than a weekly injection. Better adherence means better real-world outcomes.
• Stigma: Many South Africans are uncomfortable with self-injection in shared living spaces. A pill removes this barrier entirely.

Novo Nordisk already has oral semaglutide (Rybelsus) on the market, but Rybelsus is approved only for type 2 diabetes and produces modest weight loss compared to injectable Wegovy. Amycretin would be the first oral drug to truly compete with injectable efficacy for weight management.

Amycretin vs CagriSema: Same Pathways, Different Approach

Both amycretin and CagriSema target GLP-1 and amylin receptors. But they do it very differently:

CagriSema is further along in development and has stronger weight loss data, but it is still an injectable. Novo Nordisk appears to be pursuing both approaches -- CagriSema for patients comfortable with injections who want maximum efficacy, and amycretin for the oral-preference market. Both drugs could eventually be available, serving different patient populations.

Side Effects and Safety Considerations

Phase 1 data is limited, but the side effect profile of amycretin appears consistent with other GLP-1 and amylin-based medications:

• Nausea -- the most commonly reported side effect, particularly during dose escalation. This is typical of all GLP-1 drugs and usually subsides after 2-4 weeks.
• Vomiting and diarrhoea -- reported at moderate rates, generally mild to moderate in severity.
• Decreased appetite -- this is partially the intended effect of the drug, not purely a side effect.
• No serious safety signals identified in Phase 1, though larger trials will provide more comprehensive safety data.

If you experience side effects on current GLP-1 medications like Ozempic, our semaglutide side effects guide covers general management strategies that may apply to similar drug classes.

When Will Amycretin Be Available in South Africa?

Here is a realistic timeline based on the current development stage:

• 2024-2026: Phase 2 trials (ongoing). Testing optimal dosing and confirming efficacy in larger groups.
• 2027-2028: Phase 3 trials (expected). Large-scale pivotal trials needed for regulatory submission.
• 2028-2029: Potential FDA submission and approval (earliest realistic estimate).
• 2029-2031: SAHPRA approval for South Africa. SAHPRA typically reviews new molecules 12-18 months after FDA approval, assuming Novo Nordisk submits locally.

This is a best-case scenario. Drug development timelines frequently shift. If Phase 2 results are as strong as Phase 1 suggests, Novo Nordisk may fast-track development -- the commercial prize for an effective oral obesity pill is enormous.

Will Medical Aid Cover Amycretin?

Coverage will depend on SAHPRA scheduling, the registered indication (obesity vs diabetes), and individual medical aid formularies. Based on current trends with GLP-1 medical aid coverage in South Africa:

• Discovery Health -- likely to cover if prescribed for BMI 30+ or BMI 27+ with comorbidities, similar to current Ozempic policies.
• Bonitas and Momentum -- may require PMB (Prescribed Minimum Benefit) motivation for obesity-related conditions.
• Budget medical aids -- unlikely to cover oral weight loss medications initially due to cost containment.

An oral formulation could work in amycretin's favour for medical aid coverage -- pills are simpler to manage, store, and dispense than cold-chain injectables, which may make medical aids more receptive to formulary inclusion.

What You Can Do Now While Waiting for Amycretin

Amycretin is years away from South African availability. In the meantime, evidence-based options that are available today:

• Currently available GLP-1 drugs: Ozempic and Wegovy are SAHPRA-approved and available at Dis-Chem, Clicks, and independent pharmacies across South Africa.
• Diet strategies that work with or without medication: High-protein diets preserve muscle during weight loss, intermittent fasting can complement medication effects, and calorie deficit fundamentals apply regardless of drug status.
• Exercise for body composition: Exercise while on GLP-1 medication is critical for preserving lean mass. Resistance training 2-3 times per week is the single most important adjunct to any weight loss drug.
• Muscle preservation: If you are concerned about muscle loss on semaglutide, combine your medication with adequate protein (1.2-1.6g per kg body weight daily) and strength training.

The Bottom Line on Amycretin

Amycretin represents a genuine leap forward in weight loss pharmacology -- not because it is dramatically more effective than injectable options (that remains to be confirmed in larger trials), but because it puts GLP-1-plus-amylin-level weight loss into a daily tablet. For the millions of people worldwide who want effective obesity treatment but will not self-inject, amycretin could open the door.

For South Africans, the wait will be long -- likely 2029 at the earliest. But the pipeline is promising. Between CagriSema, retatrutide, survodutide, orforglipron, and now amycretin, the next 3-5 years will bring more weight loss options to South Africa than the previous three decades combined.